Enlivex Therapeutics (ENLV) 6-K 30 Aug 24 Condensed Consolidated Financial Statements Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Jun. 30, 2024
Document Information Line Items
Entity Registrant Name	ENLIVEX THERAPEUTICS LTD.
Document Type	6-K
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001596812
Document Period End Date	Jun. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity File Number	001-36578

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 3,747	$ 813
Short-term interest-bearing deposits	22,195	26,507
Prepaid expenses and other receivables	2,400	1,336
Assets classified as held for sale	228	5,108
Total Current Assets	28,570	33,764
Non-Current Assets
Other receivables	898
Property and equipment, net	1,158	1,539
Other assets	1,276	1,528
Total Non-Current Assets	3,332	3,067
TOTAL ASSETS	31,902	36,831
Current Liabilities
Accounts payable	303	827
Accrued expenses and other liabilities	2,538	4,001
Liability classified as held for sale		1,233
Total Current Liabilities	2,841	6,061
Non-Current Liabilities
Other long-term liabilities	499	686
Total Non-Current Liabilities	499	686
Commitments and Contingent Liabilities
TOTAL LIABILITIES	3,340	6,747
SHAREHOLDERS’ EQUITY
Ordinary shares of NIS 0.40 par value per share Authorized: 45,000,000 shares as of June 30, 2024 and December 31, 2023; Issued and outstanding: 20,883,312 and 18,598,555 as of June 30, 2024 and December 31, 2023, respectively;	2,385	2,137
Additional paid in capital	144,405	138,939
Foreign currency translation adjustments	1,101	1,101
Accumulated deficit	(119,329)	(112,093)
TOTAL SHAREHOLDERS’ EQUITY	28,562	30,084
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 31,902	$ 36,831

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Ordinary shares, par value (in Dollars per share)	$ 0.4	$ 0.4
Ordinary shares, authorized	45,000,000	45,000,000
Ordinary shares, Issued	20,883,312	18,598,555
Ordinary shares, outstanding	20,883,312	18,598,555

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Operations And Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Revenues
Operating expenses:
Research and development expenses	1,999	5,035	4,856	10,211
General and administrative expenses	987	1,614	2,080	3,221
Loss on disposal group of assets held for sale			201
Total	2,986	6,649	7,137	13,432
Operating loss	(2,986)	(6,649)	(7,137)	(13,432)
Finance income (expense)	(110)	(143)	(99)	(578)
Net loss	$ (3,096)	$ (6,792)	$ (7,236)	$ (14,010)
Basic loss per share (in Dollars per share)	$ (0.16)	$ (0.37)	$ (0.38)	$ (0.76)
Weighted average number of shares outstanding (in Shares)	19,545,056	18,584,801	19,138,066	18,550,702

Condensed Consolidated Statem_2

Condensed Consolidated Statements Of Operations And Comprehensive Loss (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Basic & diluted loss per share	$ (0.16)	$ (0.37)	$ (0.38)	$ (0.76)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Ordinary Shares	Additional paid in capital	Currency translation reserve	Accumulated deficit	Total
Balance at Dec. 31, 2022	$ 2,117	$ 136,648	$ 1,101	$ (83,025)	$ 56,841
Balance (in Shares) at Dec. 31, 2022	18,421,852
Restricted stock units vested	$ 3	(3)
Restricted stock units vested (in Shares)	34,295
Issuance of shares for cash consideration	$ 13	305			318
Issuance of shares for cash consideration (in Shares)	110,115
Stock based compensation		633			633
Net loss				(7,218)	(7,218)
Balance at Mar. 31, 2023	$ 2,133	137,583	1,101	(90,243)	50,574
Balance (in Shares) at Mar. 31, 2023	18,566,262
Balance at Dec. 31, 2022	$ 2,117	136,648	1,101	(83,025)	56,841
Balance (in Shares) at Dec. 31, 2022	18,421,852
Net loss					(14,010)
Balance at Jun. 30, 2023	$ 2,136	138,133	1,101	(97,035)	44,335
Balance (in Shares) at Jun. 30, 2023	18,589,139
Balance at Mar. 31, 2023	$ 2,133	137,583	1,101	(90,243)	50,574
Balance (in Shares) at Mar. 31, 2023	18,566,262
Restricted stock units vested	$ 1	(1)
Restricted stock units vested (in Shares)	8,821
Exercise of options
Exercise of options (in Shares)
Issuance of shares for cash consideration	$ 2	40			42
Issuance of shares for cash consideration (in Shares)	14,056
Stock based compensation		511			511
Net loss				(6,792)	(6,792)
Balance at Jun. 30, 2023	$ 2,136	138,133	1,101	(97,035)	44,335
Balance (in Shares) at Jun. 30, 2023	18,589,139
Balance at Dec. 31, 2023	$ 2,137	138,939	1,101	(112,093)	$ 30,084
Balance (in Shares) at Dec. 31, 2023	18,598,555				18,598,555
Restricted stock units vested	$ 3	(3)
Restricted stock units vested (in Shares)	34,295
Issuance of shares for cash consideration	$ 20	504			524
Issuance of shares for cash consideration (in Shares)	178,931
Stock based compensation		383			383
Net loss				(4,140)	(4,140)
Balance at Mar. 31, 2024	$ 2,160	139,823	1,101	(116,233)	26,851
Balance (in Shares) at Mar. 31, 2024	18,811,781
Balance at Dec. 31, 2023	$ 2,137	138,939	1,101	(112,093)	$ 30,084
Balance (in Shares) at Dec. 31, 2023	18,598,555				18,598,555
Net loss					$ (7,236)
Balance at Jun. 30, 2024	$ 2,385	144,405	1,101	(119,329)	$ 28,562
Balance (in Shares) at Jun. 30, 2024	20,883,312				20,883,312
Balance at Mar. 31, 2024	$ 2,160	139,823	1,101	(116,233)	$ 26,851
Balance (in Shares) at Mar. 31, 2024	18,811,781
Restricted stock units vested	$ 1	(1)
Restricted stock units vested (in Shares)	9,755
Exercise of options
Issuance of shares for cash consideration	$ 224	4,195			4,419
Issuance of shares for cash consideration (in Shares)	2,061,776
Stock based compensation		388			388
Net loss				(3,096)	(3,096)
Balance at Jun. 30, 2024	$ 2,385	$ 144,405	$ 1,101	$ (119,329)	$ 28,562
Balance (in Shares) at Jun. 30, 2024	20,883,312				20,883,312

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023
Statement of Stockholders' Equity [Abstract]
Cash consideration	$ 5,001	$ 540	$ 43	$ 470
Net of issuance costs	$ 582	$ 16	$ 1	$ 152

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities
Net loss	$ (7,236)	$ (14,010)
Income and expenses not involving cash flows:
Depreciation	348	421
Capital gain on sale of property and equipment	(79)
Loss on short-term bank deposits	166	1,626
Gain on assets and liabilities classified as held for sale	(66)
Non-cash operating lease expenses	181	434
Share-based compensation	771	1,144
Changes in operating asset and liability items:
Decrease in prepaid expenses and other receivables	1,792	(169)
Decrease in accounts payable	(524)	(240)
Decrease in accrued expenses and other liabilities	(1,453)	(1,389)
Operating lease liabilities	(207)	(624)
Net cash used in operating activities	(6,307)	(12,807)
Cash flows from investing activities
Purchase of property and equipment	(59)	(200)
Proceeds from sale of property and equipment	171	82
Proceeds from sale of assets held for sale	54
Investment in short-term interest-bearing bank deposits	(18,774)	(34,218)
Release of short-term interest-bearing bank deposits	22,912	288
Net cash provided by (used in) investing activities	4,304	(34,048)
Cash flows from financing activities
Proceeds from issuance of shares and warrants, net	4,943	360
Proceeds from exercise of options
Net cash provided by financing activities	4,943	360
Increase (decrease) in cash and cash equivalents	2,940	(46,495)
Cash and cash equivalents - beginning of period	1,226	50,357
Cash and cash equivalents - end of period	4,166	3,862
Supplemental disclosures of cash flow information:
Cash paid for taxes
Cash received for interest, net	$ 906	$ 233

General Information

General Information	6 Months Ended
	Jun. 30, 2024
General Information [Abstract]
GENERAL INFORMATION	NOTE 1 - GENERAL INFORMATION a. General Enlivex Therapeutics Ltd. (the “Parent” and, including its consolidated subsidiaries, “we”, “us”, “our” or the “Company”) was originally incorporated on January 22, 2012 under the laws of the State of Israel. The Company is a clinical stage macrophage reprogramming immunotherapy company, developing Allocetra TM Allocetra TM The Company’s ordinary shares, par value of NIS 0.40 per share (“Ordinary Shares”), are traded under the symbol “ENLV” on both the Nasdaq Capital Market and on the Tel Aviv Stock Exchange. b. Financial Resources The Company devotes substantially all of its efforts toward research and development activities and raising capital to support such activities. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding before the Company achieves sustainable revenues and profit from operations. Research and development activities have required significant capital investment since the Company’s inception. The Company expects that its operations will require additional cash investment to pursue the Company’s research and development activities, including preclinical studies, formulation development, clinical trials and related drug manufacturing. The Company has not generated any revenues or product sales and has not achieved profitable operations or positive cash flow from operations. The Company has incurred net losses since its inception, and, as of June 30, 2024, had an accumulated deficit of $119,329 thousand. The Company expects to continue to incur losses for the foreseeable future, and the Company will need to raise additional debt or equity financing or enter into partnerships to fund its development. If the Company is not able to achieve its funding requirements, it may be required to reduce discretionary spending, may not be able to continue the development of its product candidates or may be required to delay its development programs, which could have a material adverse effect on the Company’s ability to achieve its intended business objectives. There can be no assurances that additional financing will be secured or, if secured, will be on favorable terms. The ability of the Company to transition to profitability in the longer term is dependent on developing products and product revenues to support its expenses. The Company’s management and board of directors (the “ Board

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Significant Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation These unaudited condensed consolidated financial statements include the accounts of the Company and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited annual financial statements and notes thereto included in the Company’s 2023 Annual Report on Form 20-F, as filed with the U.S. Securities and Exchange Commission on April 30, 2024. The results of operations for these interim periods are not necessarily indicative of the operating results for any future period. The December 31, 2023 financial information has been derived from the Company’s audited financial statements. Use of Estimates The preparation of interim financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts in the consolidated balance sheets and statements of operations, it also requires that management exercise its judgment in applying the Company’s accounting policies. On an ongoing basis, management evaluates its estimates, including estimates related to its stock-based compensation expense and implicit interest rate on new lease liabilities. Significant estimates in these interim financial statements include estimates made for accrued research and development expenses and stock-based compensation expenses. Functional Currency and Translation to The Reporting Currency The functional currency of the Company is the U.S. dollar because the U.S. dollar is the currency of the primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future. Balances related to non-monetary assets and liabilities are based on translated amounts as of the date of the change, and non-monetary assets acquired and liabilities were translated at the approximate exchange rate prevailing at the date of the transaction. Transactions included in the statement of income were translated at the approximate exchange rate in effect at the time of the transaction. 1 U.S. dollar = 3.759 NIS and 3.627 NIS as of June 30, 2024 and December 31, 2023, respectively. The U.S. dollar increased against the NIS 2.12%, 3.64%, 2.35% and 5.14% in the three and six month periods ended June 30, 2024 and 2023, respectively. Recently Adopted Accounting Standards During the three months ended June 30, 2024, the Company was not required to adopt any recently issued accounting standards. Recently Issued Accounting Pronouncements Not Yet Adopted In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to provide enhanced segment disclosures. The standard will require disclosures about significant segment expenses and other segment items and identifying the Chief Operating Decision Maker and how they use the reported segment profitability measures to assess segment performance and allocate resources. These enhanced disclosures are required for all entities on an interim and annual basis, even if they have only a single reportable segment. The standard is effective for years beginning after December 15, 2023 and interim periods within annual periods beginning after December 15, 2024, and early adoption is permitted. The Company does not believe that adoption of this ASU will have a material impact on the Company’s consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. The standard will require more detailed information in the rate reconciliation table and for income taxes paid, among other enhancements. The standard is effective for years beginning after December 15, 2024, early adoption is permitted. The Company does not believe that adoption of this ASU will have a material impact on the Company’s consolidated financial statements. Significant Accounting Policies There have been no material changes to the significant accounting policies previously disclosed in the Company’s Annual Report on Form 20-F for the year ended December 31, 2023.

Cash, Cash Equivalents and Rest

Cash, Cash Equivalents and Restricted Cash	6 Months Ended
	Jun. 30, 2024
Cash, Cash Equivalents and Restricted Cash [Abstract]
CASH, CASH EQUIVALENTS AND RESTRICTED CASH	NOTE 3 – CASH, CASH EQUIVALENTS AND RESTRICTED CASH June 30, December 31, (in thousands) 2024 2023 Cash held in banks $ 3,747 $ 813 Total cash and cash equivalents 3,747 813 Restricted cash – current – Prepaid expenses and other receivables 113 113 Restricted cash – noncurrent – Other assets 306 300 Total cash, cash equivalents and restricted cash shown in the statement of cash flows $ 4,166 $ 1,226

Short Term Deposits

Short Term Deposits	6 Months Ended
	Jun. 30, 2024
Short Term Deposits [Abstract]
SHORT TERM DEPOSITS	NOTE 4 – SHORT TERM DEPOSITS June 30, December 31, (in thousands) 2024 2023 Bank deposits in U.S.$ (annual average interest rates 5.86% and 6.195%) $ 9,652 $ 6,240 Bank deposits in NIS (annual average interest rates 4.317% and 4.568%) 12,543 20,267 Total short-term deposits $ 22,195 $ 26,507

Prepaid Expenses and Other Rece

Prepaid Expenses and Other Receivables	6 Months Ended
	Jun. 30, 2024
Prepaid Expenses and Other Receivables [Abstract]
PREPAID EXPENSES AND OTHER RECEIVABLES	NOTE 5 – PREPAID EXPENSES AND OTHER RECEIVABLES June 30, December 31, (in thousands) 2024 2023 Prepaid expenses $ 1,141 $ 1,107 Tax authorities 47 116 Others 1,212 113 $ 2,400 $ 1,336

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2024
Property and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 6 – PROPERTY AND EQUIPMENT Property and equipment, net consists of the following: June 30, December 31, (in thousands) 2024 2023 Cost: Laboratory equipment $ 2,130 $ 2,412 Computers 431 380 Office furniture & equipment 184 186 Leasehold improvements 1,431 1,431 Total cost 4,176 4,409 Accumulated depreciation: Laboratory equipment 1,876 1,891 Computers 296 263 Office furniture & equipment 47 40 Leasehold improvements 799 676 Total accumulated depreciation 3,018 2,870 Depreciated cost $ 1,158 $ 1,539 Depreciation expenses for the three and six month periods ended June 30, 2024 and 2023 were $160, $348, $212 and $421 thousand, respectively.

Other Assets

Other Assets	6 Months Ended
	Jun. 30, 2024
Other Assets [Abstract]
OTHER ASSETS	NOTE 7 – OTHER ASSETS June 30, December 31, (in thousands) 2024 2023 Restricted cash $ 306 $ 300 Long Term Deposit 8 8 Long-term prepaid expenses 92 179 Right-of-Use assets, net 870 1,041 $ 1,276 $ 1,528

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	6 Months Ended
	Jun. 30, 2024
Accrued Expenses and Other Liabilities [Abstract]
ACCRUED EXPENSES AND OTHER LIABILITIES	NOTE 8 – ACCRUED EXPENSES AND OTHER LIABILITIES June 30, December 31, (in thousands) 2024 2023 Vacation, convalescence and bonus accruals $ 291 $ 341 Employees and payroll related 314 422 Short term operating lease liabilities 336 346 Accrued expenses and other 1,597 2,892 $ 2,538 $ 4,001

Leases

Leases	6 Months Ended
	Jun. 30, 2024
Leases [Abstract]
LEASES	NOTE 9 – LEASES The Company is a party to operating leases for its corporate offices, laboratory space, plant space and vehicles. Six months ended (in thousands) 2024 2023 The components of lease expense were as follows: Operating leases expenses $ 207 $ 522 Supplemental consolidated cash flow information related to operating leases follows: Cash used in operating activities $ 212 $ 520 Non-cash activity: Right of use assets obtained in exchange for new operating lease liabilities $ 25 $ 145 June 30, December 31, (in thousands) 2024 2023 Supplemental information related to operating leases, including location of amounts reported in the accompanying consolidated balance sheets, follows: Other assets - Right-of-Use assets $ 1,722 $ 2,161 Accumulated amortization 852 1,120 Operating lease Right-of-Use assets, net $ 870 $ 1,041 Lease liabilities – current - Accounts payable and accrued liabilities $ 336 $ 346 Lease liabilities – noncurrent 499 686 Total operating lease liabilities $ 835 $ 1,032 Weighted average remaining lease term in years 2.89 3.3 Weighted average annual discount rate 6.8 % 6.7 % Maturities of operating lease liabilities as of June 30, 2024, were as follows: 2024 (after June 30) $ 191 2025 355 2026 193 2027 117 2028 and onwards 89 Total undiscounted lease liability 945 Less: Imputed interest (110 ) Present value of lease liabilities $ 835

Commitments and Contingent Liab

Commitments and Contingent Liabilities	6 Months Ended
	Jun. 30, 2024
Commitments and Contingent Liabilities [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 10 – COMMITMENTS AND CONTINGENT LIABILITIES The Company is required to pay royalties to the State of Israel (represented by the Israeli Innovation Authority (the “ IIA The gross amount of grants received by the Company from the IIA, including accrued interest as of June 30, 2024, was approximately 9.9 million. As of June 30, 2024, the Company had not paid any royalties to the IIA.

Equity

Equity	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
EQUITY	NOTE 11 – EQUITY a) On May 27, 2024, the Company entered into a securities purchase agreement with a single institutional investor in connection with the issuance and sale by the Company in a registered direct offering (the “Offering”) of (i) 2,060,000 Ordinary Shares, (ii) pre-funded warrants to purchase up to 1,511,429 Ordinary Shares (the “Pre-Funded Warrants”), (iii) Series A warrants to purchase up to 3,571,429 Ordinary Shares (the “Series A Warrants”) and (iv) Series B warrants to purchase up to 3,571,429 Ordinary Shares (the “Series B Warrants” and, together with the Series A Warrants, the “Investor Warrants”), at a combined purchase price of (a) $1.40 per Ordinary Share and the associated Investor Warrants, each to purchase one Ordinary Share, and (b) $1.399 per Pre-Funded Warrant and the associated Investor Warrants, each to purchase one Ordinary Share, pursuant to the Company’s effective shelf registration statement on Form F-3 (File No. 333-364561) and related base prospectus and prospectus supplement. Each Investor Warrant has an exercise price of $1.40 per Ordinary Share and is immediately exercisable. The Series A Warrants expire upon the earlier of 18 months following the issuance date and 60 days following the Company’s public announcement of positive topline trail results of Allocetra TM TM H.C. Wainwright & Co. (“Wainwright”) acted as placement agent in connection with the Offering, and in consideration therefor the Company agreed to register and issue to Wainwright warrants (the “Placement Agent Warrants”, and together with the Investor Warrants and the Pre-Funded Warrants, the “Warrants”) to purchase up to 250,000 Ordinary Shares. The Placement Agent Warrants comprise Series A Warrants to purchase 125,000 Ordinary Shares and Series B Warrants to purchase 125,000 Ordinary Shares, containing the same terms as the Investor Warrants, except that they are exercisable at a price of $1.75 per Ordinary Share, and the Series B Warrants will expire upon the earlier of five years following the commencement of the sale of the securities offered in the Offering and 60 days following the Company’s public announcement of its filing with the FDA for approval for Allocetra TM In addition, the Company agreed to pay Wainwright an aggregate cash fee equal to 7% of the gross proceeds raised in the Offering, a management fee equal to 1% of the gross proceeds raised in the Offering and $90,950 for various fees and expenses. The closing of the Offering occurred on May 29, 2024. The net proceeds from the Offering were approximately $4.5 million after deducting Wainwright’s fees and other expenses relating to the Offering. The Company intends to use the net proceeds from the Offering for working capital and other general corporate purposes. b) All Company warrants are classified as components of shareholders’ equity because such warrants are free standing financial instruments that are legally detachable, separately exercisable, do not embody an obligation for the Company to repurchase its own shares and permit the holders to receive a fixed number of Ordinary Shares upon exercise, require physical settlement and do not provide any guarantee of value or return (unless, in accordance with ASC 815-40-55-3, there is a fundamental transaction, as defined in the warrant agreements, which allows the holders of the warrants to receive the same form of consideration payable to the holders of Ordinary Shares, in which case equity treatment is not precluded). Number of Warrants Weighted average exercise price Outstanding January 1, 2024 202,251 $ 23.31 Issued 8,904,287 $ 1.17 Outstanding and exercisable June 30, 2024 9,106,538 $ 1.66 Composed of: Number of Exercise Issuance Expiration 22,750 $ 10.00 February 26, 2020 February 24, 2025 160,727 $ 25.00 February 12, 2021 February 9, 2026 18,774 $ 25.00 February 17, 2021 February 9, 2026 1,511,429 $ 0.001 May 29, 2024 No expiration date 3,571,429 $ 1.40 May 29, 2024 December 1, 2025(i) 3,571,429 $ 1.40 May 29, 2024 November 29, 2029 (ii) 125,000 $ 1.75 May 29, 2024 December 1, 2025(i) 125,000 $ 1.75 May 29, 2024 May 27, 2029 (iii) 9,106,538 (i) The earlier of (a) December 1, 2025 and (b) the 60th day following the occurrence of the Series A Milestone Event. (ii) The earlier of (a) November 29, 2029 and (b) the 60th day following the occurrence of the Series B Milestone Event. (iii) The earlier of (a) May 27, 2029 and (b) 60 days following the Company’s public announcement of its filing with the FDA for approval for Allocetra TM c) During the six months ended June 30, 2024 the Company issued 180,707 Ordinary Shares under our ATM agreement with Cantor Fitzgerald & Co. and JMP Securities LLC for a gross consideration of $543 thousand net of $16 thousand of issuance expenses.

Share-Based Compensation

Share-Based Compensation	6 Months Ended
	Jun. 30, 2024
Share-Based Compensation [Abstract]
SHARE-BASED COMPENSATION	NOTE 12 – SHARE-BASED COMPENSATION a) As of June 30, 2024, 5,028,704 Ordinary Shares were authorized for issuance to employees, directors and consultants under the 2019 Equity Incentive Plan (the “2019 Plan”), of which 966,057 shares remained available for future grant. b) The following table contains information concerning options granted under the 2019 Plan : Three months ended 2024 2023 Number of options Weighted average exercise price Number of options Weighted Outstanding at beginning of period 3,007,624 $ 5.41 2,929,868 $ 5.84 Forfeited and expired (21,921 ) $ 5.06 (14,375 ) $ 6.82 Outstanding at end of period 2,985,703 $ 5.41 2,915,493 $ 5.84 Exercisable at end of period 2,228,902 $ 5.67 2,090,378 $ 5.59 Non-vested at beginning of period 772,301 $ 4.67 876,851 $ 6.48 Vested - $ - (37,861 ) $ 11.13 Forfeited (13,750 ) $ 3.79 (13,875 ) $ 5.90 Non-vested at the end of period 758,551 $ 4.6 8 825,115 $ 6.27 Six months ended 2024 2023 Number of Weighted Number of options Weighted Outstanding at beginning of period 2,842,496 $ 5.63 2,939,434 $ 5.85 Granted 250,000 $ 3.21 - $ - Forfeited and expired (106,793 ) $ 6.00 (23,941 ) $ 6.71 Outstanding at end of period 2,985,703 $ 5.41 2,915,493 $ 5.84 Exercisable at end of period 2,228,902 $ 5.67 2,090,378 $ 5.59 Non vested at beginning of period 596,503 $ 5.53 986,005 $ 6.46 Granted 250,000 $ 3.21 - $ - Forfeited and expired (24,313 ) $ 5.04 (15,375 ) $ 6.73 vested (63,639 ) $ 6.75 (145,515 ) $ 7.44 Outstanding at end of period 758,551 $ 4.68 825,115 $ 6.27 During the three and six month periods ended June 30, 2024 and 2023, the Company recognized $237, $460, $427 and $957 thousand, respectively, of share-based compensation expenses related to stock options. As of June 30, 2024, the total unrecognized estimated compensation cost related to outstanding non-vested stock options was $1,061 thousand, which is expected to be recognized over a weighted average period of 1.36 years. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (UNAUDITED) c) Set forth below is data regarding the range of exercise prices and remaining contractual life for all options outstanding at June 30, 2024: Exercise price Number of options Remaining Intrinsic Value No. of options $ 2.69 649,591 0.92 $ - 649,591 $ 3.21 240,000 9.63 - - $ 3.53 53,192 9.35 - - $ 3.66 250,000 5.84 - 250,000 $ 4.68 34,500 5.75 - 34,500 $ 5.34 160,750 7.75 - 84,000 $ 5.34 442,410 8.39 - 178,176 $ 5.96 150,000 8.39 - 37,500 $ 6.22 552,883 2.67 - 552,883 $ 8.19 150,000 5.39 - 150,000 $ 9.02 40,500 6.38 - 30,375 $ 10.12 10,407 4.43 - 10,407 $ 12.23 250,000 6.91 - 250,000 $ 21.40 970 5.07 - 970 $ 90.16 500 0.42 - 500 2,985,703 $ - 2,228,902 d) The following table contains information concerning restricted stock units granted under the 2019 Plan: Three months ended 2024 2023 Number Weighted Number Weighted Nonvested at beginning of period 571,460 $ 2.65 114,329 $ 9.97 Granted $ - $ - Vested (3,444 ) $ 10.28 (3,438 ) $ 10.28 Forfeited (5,757 ) $ 3.87 (313 ) $ 14.67 Nonvested at end of period 562,259 $ 2.59 110,578 $ 9.95 Six months ended 2024 2023 Number Weighted Number Weighted Nonvested at beginning of period 621,135 $ 3.14 157,560 $ 10.02 Granted - $ - - $ - Vested (44,050 ) $ 9.9 (46,544 ) $ 10.15 Forfeited (14,826 ) $ 3.64 (438 ) $ 14.67 Nonvested at end of period 562,259 $ 2.59 110,578 $ 9.95 The Company estimates the fair value of restricted stock units based on the closing sales price of the Ordinary Shares on the date of grant (or the closing bid price, if no sales were reported). For the three and six month periods ended June 30, 2024 and 2023, the Company recognized $151, $311, $84 and $187 thousand, respectively, of share-based compensation expense related to restricted stock units. Total share-based compensation expense related to restricted stock units not yet recognized as of June 30, 2024 was $653 thousand, which is expected to be recognized over a weighted average period of 1.27 years. e) The following table summarizes share-based compensation expenses included in the statements of operations related to grants under the 2019 Plan: Three months ended Six months ended (in thousands) 2024 2023 2024 2023 Research & development $ 145 $ 122 $ 269 $ 318 General & administrative 243 389 502 826 Total $ 388 $ 511 $ 771 $ 1,144

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2024
Fair Value Measurement [Abstract]
FAIR VALUE MEASUREMENT	NOTE 13 – FAIR VALUE MEASUREMENT The Company’s financial assets and liabilities measured at fair value on a recurring basis consisted of the following types of instruments as of June 30, 2024 and December 31, 2023: (in thousands ) June 30, 2024 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 3,747 $ $ - $ - Short term deposits 22,195 - - Restricted cash 306 - - Total financial assets $ 26,248 $ $ - $ - (in thousands ) December 31, 2023 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 813 $ 813 $ - $ - Short term deposits 26,507 26,507 - - Restricted cash 413 413 - - Total financial assets $ 27,733 $ 27,733 $ - $ -

Events Subsequent to the Balanc

Events Subsequent to the Balance Sheet Date	6 Months Ended
	Jun. 30, 2024
Events Subsequent to the Balance Sheet Date [Abstract]
EVENTS SUBSEQUENT TO THE BALANCE SHEET DATE	NOTE 14 – EVENTS SUBSEQUENT TO THE BALANCE SHEET DATE The Company evaluated all events and transactions that occurred subsequent to the balance sheet date and prior to the date on which these unaudited condensed consolidated financial statements were issued and determined that the following subsequent event necessitated disclosure: 1. In July 2024, 518,429 Pre-Funded Warrants were exercised for 518,429 Ordinary Shares.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2024
Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These unaudited condensed consolidated financial statements include the accounts of the Company and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited annual financial statements and notes thereto included in the Company’s 2023 Annual Report on Form 20-F, as filed with the U.S. Securities and Exchange Commission on April 30, 2024. The results of operations for these interim periods are not necessarily indicative of the operating results for any future period. The December 31, 2023 financial information has been derived from the Company’s audited financial statements.
Use of Estimates	Use of Estimates The preparation of interim financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts in the consolidated balance sheets and statements of operations, it also requires that management exercise its judgment in applying the Company’s accounting policies. On an ongoing basis, management evaluates its estimates, including estimates related to its stock-based compensation expense and implicit interest rate on new lease liabilities. Significant estimates in these interim financial statements include estimates made for accrued research and development expenses and stock-based compensation expenses.
Functional Currency and Translation to The Reporting Currency	Functional Currency and Translation to The Reporting Currency The functional currency of the Company is the U.S. dollar because the U.S. dollar is the currency of the primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future. Balances related to non-monetary assets and liabilities are based on translated amounts as of the date of the change, and non-monetary assets acquired and liabilities were translated at the approximate exchange rate prevailing at the date of the transaction. Transactions included in the statement of income were translated at the approximate exchange rate in effect at the time of the transaction. 1 U.S. dollar = 3.759 NIS and 3.627 NIS as of June 30, 2024 and December 31, 2023, respectively. The U.S. dollar increased against the NIS 2.12%, 3.64%, 2.35% and 5.14% in the three and six month periods ended June 30, 2024 and 2023, respectively.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards During the three months ended June 30, 2024, the Company was not required to adopt any recently issued accounting standards.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to provide enhanced segment disclosures. The standard will require disclosures about significant segment expenses and other segment items and identifying the Chief Operating Decision Maker and how they use the reported segment profitability measures to assess segment performance and allocate resources. These enhanced disclosures are required for all entities on an interim and annual basis, even if they have only a single reportable segment. The standard is effective for years beginning after December 15, 2023 and interim periods within annual periods beginning after December 15, 2024, and early adoption is permitted. The Company does not believe that adoption of this ASU will have a material impact on the Company’s consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. The standard will require more detailed information in the rate reconciliation table and for income taxes paid, among other enhancements. The standard is effective for years beginning after December 15, 2024, early adoption is permitted. The Company does not believe that adoption of this ASU will have a material impact on the Company’s consolidated financial statements.
Significant Accounting Policies	Significant Accounting Policies There have been no material changes to the significant accounting policies previously disclosed in the Company’s Annual Report on Form 20-F for the year ended December 31, 2023.

Cash, Cash Equivalents and Re_2

Cash, Cash Equivalents and Restricted Cash (Tables)	6 Months Ended
	Jun. 30, 2024
Cash, Cash Equivalents and Restricted Cash [Abstract]
Schedule of Cash and Cash Equivalents and Restricted Cash	June 30, December 31, (in thousands) 2024 2023 Cash held in banks $ 3,747 $ 813 Total cash and cash equivalents 3,747 813 Restricted cash – current – Prepaid expenses and other receivables 113 113 Restricted cash – noncurrent – Other assets 306 300 Total cash, cash equivalents and restricted cash shown in the statement of cash flows $ 4,166 $ 1,226

Short Term Deposits (Tables)

Short Term Deposits (Tables)	6 Months Ended
	Jun. 30, 2024
Short Term Deposits [Abstract]
Schedule of Short Term Deposits	June 30, December 31, (in thousands) 2024 2023 Bank deposits in U.S.$ (annual average interest rates 5.86% and 6.195%) $ 9,652 $ 6,240 Bank deposits in NIS (annual average interest rates 4.317% and 4.568%) 12,543 20,267 Total short-term deposits $ 22,195 $ 26,507

Prepaid Expenses and Other Re_2

Prepaid Expenses and Other Receivables (Tables)	6 Months Ended
	Jun. 30, 2024
Prepaid Expenses and Other Receivables [Abstract]
Schedule of Prepaid Expenses and Other Receivables	June 30, December 31, (in thousands) 2024 2023 Prepaid expenses $ 1,141 $ 1,107 Tax authorities 47 116 Others 1,212 113 $ 2,400 $ 1,336

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2024
Property and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net consists of the following: June 30, December 31, (in thousands) 2024 2023 Cost: Laboratory equipment $ 2,130 $ 2,412 Computers 431 380 Office furniture & equipment 184 186 Leasehold improvements 1,431 1,431 Total cost 4,176 4,409 Accumulated depreciation: Laboratory equipment 1,876 1,891 Computers 296 263 Office furniture & equipment 47 40 Leasehold improvements 799 676 Total accumulated depreciation 3,018 2,870 Depreciated cost $ 1,158 $ 1,539

Other Assets (Tables)

Other Assets (Tables)	6 Months Ended
	Jun. 30, 2024
Other Assets [Abstract]
Schedule of Other Assets	June 30, December 31, (in thousands) 2024 2023 Restricted cash $ 306 $ 300 Long Term Deposit 8 8 Long-term prepaid expenses 92 179 Right-of-Use assets, net 870 1,041 $ 1,276 $ 1,528

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities (Tables)	6 Months Ended
	Jun. 30, 2024
Accrued Expenses and Other Liabilities [Abstract]
Schedule of Accrued Expenses and Other Liabilities	ACCRUED EXPENSES AND OTHER LIABILITIES June 30, December 31, (in thousands) 2024 2023 Vacation, convalescence and bonus accruals $ 291 $ 341 Employees and payroll related 314 422 Short term operating lease liabilities 336 346 Accrued expenses and other 1,597 2,892 $ 2,538 $ 4,001

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2024
Leases [Abstract]
Schedule of Operating Lease	The Company is a party to operating leases for its corporate offices, laboratory space, plant space and vehicles. Six months ended (in thousands) 2024 2023 The components of lease expense were as follows: Operating leases expenses $ 207 $ 522 Supplemental consolidated cash flow information related to operating leases follows: Cash used in operating activities $ 212 $ 520 Non-cash activity: Right of use assets obtained in exchange for new operating lease liabilities $ 25 $ 145
Schedule of Supplemental Information Related to Operating Leases	June 30, December 31, (in thousands) 2024 2023 Supplemental information related to operating leases, including location of amounts reported in the accompanying consolidated balance sheets, follows: Other assets - Right-of-Use assets $ 1,722 $ 2,161 Accumulated amortization 852 1,120 Operating lease Right-of-Use assets, net $ 870 $ 1,041 Lease liabilities – current - Accounts payable and accrued liabilities $ 336 $ 346 Lease liabilities – noncurrent 499 686 Total operating lease liabilities $ 835 $ 1,032 Weighted average remaining lease term in years 2.89 3.3 Weighted average annual discount rate 6.8 % 6.7 %
Schedule of Maturities of Operating Lease Liabilities	Maturities of operating lease liabilities as of June 30, 2024, were as follows: 2024 (after June 30) $ 191 2025 355 2026 193 2027 117 2028 and onwards 89 Total undiscounted lease liability 945 Less: Imputed interest (110 ) Present value of lease liabilities $ 835

Equity (Tables)

Equity (Tables)	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Schedule of Number of Ordinary Shares Upon Exercise	Number of Warrants Weighted average exercise price Outstanding January 1, 2024 202,251 $ 23.31 Issued 8,904,287 $ 1.17 Outstanding and exercisable June 30, 2024 9,106,538 $ 1.66
Schedule of Changes in Exercisable Ordinary Shares Warrants	Composed of: Number of Exercise Issuance Expiration 22,750 $ 10.00 February 26, 2020 February 24, 2025 160,727 $ 25.00 February 12, 2021 February 9, 2026 18,774 $ 25.00 February 17, 2021 February 9, 2026 1,511,429 $ 0.001 May 29, 2024 No expiration date 3,571,429 $ 1.40 May 29, 2024 December 1, 2025(i) 3,571,429 $ 1.40 May 29, 2024 November 29, 2029 (ii) 125,000 $ 1.75 May 29, 2024 December 1, 2025(i) 125,000 $ 1.75 May 29, 2024 May 27, 2029 (iii) 9,106,538 (i) The earlier of (a) December 1, 2025 and (b) the 60th day following the occurrence of the Series A Milestone Event. (ii) The earlier of (a) November 29, 2029 and (b) the 60th day following the occurrence of the Series B Milestone Event. (iii) The earlier of (a) May 27, 2029 and (b) 60 days following the Company’s public announcement of its filing with the FDA for approval for Allocetra TM

Share-Based Compensation (Table

Share-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2024
Share-Based Compensation [Abstract]
Schedule of Employees and Directors Stock Options Granted Under the 2019 Plan	The following table contains information concerning options granted under the 2019 Plan : Three months ended 2024 2023 Number of options Weighted average exercise price Number of options Weighted Outstanding at beginning of period 3,007,624 $ 5.41 2,929,868 $ 5.84 Forfeited and expired (21,921 ) $ 5.06 (14,375 ) $ 6.82 Outstanding at end of period 2,985,703 $ 5.41 2,915,493 $ 5.84 Exercisable at end of period 2,228,902 $ 5.67 2,090,378 $ 5.59 Non-vested at beginning of period 772,301 $ 4.67 876,851 $ 6.48 Vested - $ - (37,861 ) $ 11.13 Forfeited (13,750 ) $ 3.79 (13,875 ) $ 5.90 Non-vested at the end of period 758,551 $ 4.6 8 825,115 $ 6.27 Six months ended 2024 2023 Number of Weighted Number of options Weighted Outstanding at beginning of period 2,842,496 $ 5.63 2,939,434 $ 5.85 Granted 250,000 $ 3.21 - $ - Forfeited and expired (106,793 ) $ 6.00 (23,941 ) $ 6.71 Outstanding at end of period 2,985,703 $ 5.41 2,915,493 $ 5.84 Exercisable at end of period 2,228,902 $ 5.67 2,090,378 $ 5.59 Non vested at beginning of period 596,503 $ 5.53 986,005 $ 6.46 Granted 250,000 $ 3.21 - $ - Forfeited and expired (24,313 ) $ 5.04 (15,375 ) $ 6.73 vested (63,639 ) $ 6.75 (145,515 ) $ 7.44 Outstanding at end of period 758,551 $ 4.68 825,115 $ 6.27
Schedule of Exercise Prices and Remaining Contractual Life	Set forth below is data regarding the range of exercise prices and remaining contractual life for all options outstanding at June 30, 2024: Exercise price Number of options Remaining Intrinsic Value No. of options $ 2.69 649,591 0.92 $ - 649,591 $ 3.21 240,000 9.63 - - $ 3.53 53,192 9.35 - - $ 3.66 250,000 5.84 - 250,000 $ 4.68 34,500 5.75 - 34,500 $ 5.34 160,750 7.75 - 84,000 $ 5.34 442,410 8.39 - 178,176 $ 5.96 150,000 8.39 - 37,500 $ 6.22 552,883 2.67 - 552,883 $ 8.19 150,000 5.39 - 150,000 $ 9.02 40,500 6.38 - 30,375 $ 10.12 10,407 4.43 - 10,407 $ 12.23 250,000 6.91 - 250,000 $ 21.40 970 5.07 - 970 $ 90.16 500 0.42 - 500 2,985,703 $ - 2,228,902
Schedule of Restricted Stock Units Granted Under the 2019 Plan	The following table contains information concerning restricted stock units granted under the 2019 Plan: Three months ended 2024 2023 Number Weighted Number Weighted Nonvested at beginning of period 571,460 $ 2.65 114,329 $ 9.97 Granted $ - $ - Vested (3,444 ) $ 10.28 (3,438 ) $ 10.28 Forfeited (5,757 ) $ 3.87 (313 ) $ 14.67 Nonvested at end of period 562,259 $ 2.59 110,578 $ 9.95 Six months ended 2024 2023 Number Weighted Number Weighted Nonvested at beginning of period 621,135 $ 3.14 157,560 $ 10.02 Granted - $ - - $ - Vested (44,050 ) $ 9.9 (46,544 ) $ 10.15 Forfeited (14,826 ) $ 3.64 (438 ) $ 14.67 Nonvested at end of period 562,259 $ 2.59 110,578 $ 9.95
Schedule of Share-Based Compensation Expenses Related to Grants Under the 2019 Plan	The following table summarizes share-based compensation expenses included in the statements of operations related to grants under the 2019 Plan: Three months ended Six months ended (in thousands) 2024 2023 2024 2023 Research & development $ 145 $ 122 $ 269 $ 318 General & administrative 243 389 502 826 Total $ 388 $ 511 $ 771 $ 1,144

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2024
Fair Value Measurement [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	The Company’s financial assets and liabilities measured at fair value on a recurring basis consisted of the following types of instruments as of June 30, 2024 and December 31, 2023: (in thousands ) June 30, 2024 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 3,747 $ $ - $ - Short term deposits 22,195 - - Restricted cash 306 - - Total financial assets $ 26,248 $ $ - $ - (in thousands ) December 31, 2023 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 813 $ 813 $ - $ - Short term deposits 26,507 26,507 - - Restricted cash 413 413 - - Total financial assets $ 27,733 $ 27,733 $ - $ -

General Information (Details)

General Information (Details) $ / shares in Units, $ in Thousands	Jun. 30, 2024 USD ($) $ / shares	Jun. 30, 2024 ₪ / shares	Dec. 31, 2023 USD ($) $ / shares
General Information [Line Items]
Par value | $ / shares	$ 0.4		$ 0.4
Accumulated deficit | $	$ (119,329)		$ (112,093)
Common Stock [Member]
General Information [Line Items]
Par value | ₪ / shares		₪ 0.4

Significant Accounting Polici_2

Significant Accounting Policies (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Significant Accounting Policies [Line Items]
Functional currency increased percentage	2.12%	2.35%	3.64%	5.14%
NIS [Member]
Significant Accounting Policies [Line Items]
Exchange rate	3.759		3.759		3.627

Cash, Cash Equivalents and Re_3

Cash, Cash Equivalents and Restricted Cash (Details) - Schedule of Cash and Cash Equivalents and Restricted Cash - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
Schedule of Cash and Cash Equivalents and Restricted Cash [Abstract]
Cash held in banks	$ 3,747	$ 813
Total cash and cash equivalents	3,747	813
Restricted cash – current – Prepaid expenses and other receivables	113	113
Restricted cash – noncurrent – Other assets	306	300
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 4,166	$ 1,226	$ 3,862	$ 50,357

Short Term Deposits (Details) -

Short Term Deposits (Details) - Schedule of Short Term Deposits - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Schedule of Short Term Deposits [Line Items]
Total short-term deposits	$ 22,195	$ 26,507
U.S [Member]
Schedule of Short Term Deposits [Line Items]
Bank deposits	9,652	6,240
NIS [Member]
Schedule of Short Term Deposits [Line Items]
Bank deposits	$ 12,543	$ 20,267

Short Term Deposits (Details)_2

Short Term Deposits (Details) - Schedule of Short Term Deposits (Parentheticals)	Jun. 30, 2024	Dec. 31, 2023
U.S [Member]
Schedule of Short Term Deposits [Line Items]
Average annual interest rates	5.86%	6.195%
NIS [Member]
Schedule of Short Term Deposits [Line Items]
Average annual interest rates	4.317%	4.568%

Prepaid Expenses and Other Re_3

Prepaid Expenses and Other Receivables (Details) - Schedule of Prepaid Expenses and Other Receivables - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Schedule of Prepaid Expenses and Other Receivables [Abstract]
Prepaid expenses	$ 1,141	$ 1,107
Tax authorities	47	116
Others	1,212	113
Total	$ 2,400	$ 1,336

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Property and Equipment [Abstract]
Depreciation expenses	$ 160	$ 348	$ 212	$ 421

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of Property and Equipment - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Total cost	$ 4,176	$ 4,409
Total accumulated depreciation	3,018	2,870
Depreciated cost	1,158	1,539
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Total cost	2,130	2,412
Total accumulated depreciation	1,876	1,891
Computers [Member]
Property, Plant and Equipment [Line Items]
Total cost	431	380
Total accumulated depreciation	296	263
Office furniture & equipment [Member]
Property, Plant and Equipment [Line Items]
Total cost	184	186
Total accumulated depreciation	47	40
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Total cost	1,431	1,431
Total accumulated depreciation	$ 799	$ 676

Other Assets (Details) - Schedu

Other Assets (Details) - Schedule of Other Assets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Schedule of Other Assets [Abstract]
Restricted cash	$ 306	$ 300
Long Term Deposit	8	8
Long-term prepaid expenses	92	179
Right-of-Use assets, net	870	1,041
Total	$ 1,276	$ 1,528

Accrued Expenses and Other Li_3

Accrued Expenses and Other Liabilities (Details) - Schedule of Accrued Expenses and Other Liabilities - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Schedule of Accrued Expenses and Other Liabilities [Abstract]
Vacation, convalescence and bonus accruals	$ 291	$ 341
Employees and payroll related	314	422
Short term operating lease liabilities	336	346
Accrued expenses and other	1,597	2,892
Accrued expenses and other liabilities, total	$ 2,538	$ 4,001

Leases (Details) - Schedule of

Leases (Details) - Schedule of Operating Lease - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
The components of lease expense were as follows:
Operating leases expenses	$ 207	$ 522
Supplemental consolidated cash flow information related to operating leases follows:
Cash used in operating activities	212	520
Non-cash activity:
Right of use assets obtained in exchange for new operating lease liabilities	$ 25	$ 145

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of Supplemental Information Related to Operating Leases - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Schedule of Supplemental Information Related to Operating Leases [Abstract]
Other assets - Right-of-Use assets	$ 1,722	$ 2,161
Accumulated amortization	852	1,120
Operating lease Right-of-Use assets, net	870	1,041
Lease liabilities – current - Accounts payable and accrued liabilities	336	346
Lease liabilities – noncurrent	499	686
Total operating lease liabilities	$ 835	$ 1,032
Weighted average remaining lease term in years	2 years 10 months 20 days	3 years 3 months 18 days
Weighted average annual discount rate	6.80%	6.70%

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of Maturities of Operating Lease Liabilities - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Schedule of Maturities of Operating Lease Liabilities [Abstract]
2024 (after June 30)	$ 191
2025	355
2026	193
2027	117
2028 and onwards	89
Total undiscounted lease liability	945
Less: Imputed interest	(110)
Present value of lease liabilities	$ 835	$ 1,032

Commitments and Contingent Li_2

Commitments and Contingent Liabilities (Details) $ in Millions	6 Months Ended
	Jun. 30, 2024 USD ($)
Commitments and Contingent Liabilities [Line Items]
Repayment of grants percentage	100%
Grants received including accrued interest (in Dollars)	$ 9.9
Minimum [Member]
Commitments and Contingent Liabilities [Line Items]
Percentage of royalties in sales	3%
Maximum [Member]
Commitments and Contingent Liabilities [Line Items]
Percentage of royalties in sales	5%

Equity (Details)

Equity (Details) - USD ($) $ / shares in Units, $ in Thousands			6 Months Ended
	May 29, 2024	May 27, 2024	Jun. 30, 2024
Equity [Line Items]
Issuance of shares			180,707
Cash fee percentage			7%
Management fee percentage			1%
Various fees and expenses related to offering (in Dollars)			$ 90,950
Net proceeds from the offering on may 2024 (in Dollars)	$ 4,500
Gross consideration from ATM (in Dollars)			543
Issuance expenses from ATM (in Dollars)			$ 16
Warrant [Member]
Equity [Line Items]
Pre- funded warrants		1,511,429
Exercise price pre-funded warrants (in Dollars per share)			$ 0.001
Series A Warrant [Member]
Equity [Line Items]
Series A warrants		3,571,429
Exercise price of warrant (in Dollars per share)		$ 1.4
Warrants expire term			18 months
Placement agent warrants			125,000
Exercise price placement agent warrants (in Dollars per share)			$ 1.75
Series B Warrants [Member]
Equity [Line Items]
Series B warrants		3,571,429
Exercise price of warrant (in Dollars per share)		$ 1.4
Warrants expire term			5 years
Warrants expire upon earlier			five and one-half years
Placement agent warrants			125,000
Exercise price placement agent warrants (in Dollars per share)			$ 1.75
Ordinary Shares [Member]
Equity [Line Items]
Issuance of shares		2,060,000

Equity (Details) - Schedule of

Equity (Details) - Schedule of Number of Ordinary Shares Upon Exercise - Warrants [Member]	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Schedule of Number of Ordinary Shares Upon Exercise [Line Items]
Number of Warrants Outstanding | shares	202,251
Weighted average exercise price Outstanding | $ / shares	$ 23.31
Number of Warrants Issued | shares	8,904,287
Weighted average exercise price Issued | $ / shares	$ 1.17
Number of Warrants Outstanding | shares	9,106,538
Weighted average exercise price Outstanding | $ / shares	$ 1.66

Equity (Details) - Schedule o_2

Equity (Details) - Schedule of Changes in Exercisable Ordinary Shares Warrants - Warrant [Member]	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Schedule of Changes in Exercisable Ordinary Shares Warrants [Line Items]
Number of Warrants	9,106,538
10.00 [Member]
Schedule of Changes in Exercisable Ordinary Shares Warrants [Line Items]
Number of Warrants	22,750
Exercise price per share | $ / shares	$ 10
Issuance date	Feb. 26, 2020
Expiration date	Feb. 24, 2025
25.00 [Member]
Schedule of Changes in Exercisable Ordinary Shares Warrants [Line Items]
Number of Warrants	160,727
Exercise price per share | $ / shares	$ 25
Issuance date	Feb. 12, 2021
Expiration date	Feb. 09, 2026
25.00 [Member]
Schedule of Changes in Exercisable Ordinary Shares Warrants [Line Items]
Number of Warrants	18,774
Exercise price per share | $ / shares	$ 25
Issuance date	Feb. 17, 2021
Expiration date	Feb. 09, 2026
0.001 [Member]
Schedule of Changes in Exercisable Ordinary Shares Warrants [Line Items]
Number of Warrants	1,511,429
Exercise price per share | $ / shares	$ 0.001
Issuance date	May 29, 2024
1.40 [Member]
Schedule of Changes in Exercisable Ordinary Shares Warrants [Line Items]
Number of Warrants	3,571,429
Exercise price per share | $ / shares	$ 1.4
Issuance date	May 29, 2024
Expiration date	Dec. 01, 2025	[1]
1.40 [Member]
Schedule of Changes in Exercisable Ordinary Shares Warrants [Line Items]
Number of Warrants	3,571,429
Exercise price per share | $ / shares	$ 1.4
Issuance date	May 29, 2024
Expiration date	Nov. 29, 2029	[2]
1.75 [Member]
Schedule of Changes in Exercisable Ordinary Shares Warrants [Line Items]
Number of Warrants	125,000
Exercise price per share | $ / shares	$ 1.75
Issuance date	May 29, 2024
Expiration date	Dec. 01, 2025	[1]
1.75 [Member]
Schedule of Changes in Exercisable Ordinary Shares Warrants [Line Items]
Number of Warrants	125,000
Exercise price per share | $ / shares	$ 1.75
Issuance date	May 29, 2024
Expiration date	May 27, 2029	[3]
[1]The earlier of (a) December 1, 2025 and (b) the 60th day following the occurrence of the Series A Milestone Event.[2]The earlier of (a) November 29, 2029 and (b) the 60th day following the occurrence of the Series B Milestone Event.[3]The earlier of (a) May 27, 2029 and (b) 60 days following the Company’s public announcement of its filing with the FDA for approval for Allocetra TM

Share-Based Compensation (Detai

Share-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share-Based Compensation [Line Items]
Share-based compensation expense	$ 388	$ 511	$ 771	$ 1,144
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation [Line Items]
Share-based compensation expense	237	460	427	957
Unrecognized estimated compensation cost	1,061		$ 1,061
Weighted average period			1 year 4 months 9 days
Restricted Stock Units [Member]
Share-Based Compensation [Line Items]
Share-based compensation expense	151	$ 311	$ 84	$ 187
Weighted average period			1 year 3 months 7 days
Share-based compensation expense not yet recognized	$ 653		$ 653
Common Stock [Member]
Share-Based Compensation [Line Items]
Ordinary shares were authorized for issuance to employe, directors and consultants (in Shares)	5,028,704		5,028,704
Shares available for future grant (in Shares)	966,057		966,057

Share-Based Compensation (Det_2

Share-Based Compensation (Details) - Schedule of Employees and Directors Stock Options Granted Under the 2019 Plan - Stock Option Plan [Member] - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Schedule of Employees and Directors Stock Options [Line Items]
Number of options, Outstanding at beginning of period	3,007,624	2,929,868	2,842,496	2,939,434
Weighted average exercise price, Outstanding at beginning of period	$ 5.41	$ 5.84	$ 5.63	$ 5.85
Number of options, Granted			250,000
Weighted average exercise price, Granted			$ 3.21
Number of options, Forfeited and expired	(21,921)	(14,375)	(106,793)	(23,941)
Weighted average exercise price, Forfeited and expired	$ 5.06	$ 6.82	$ 6	$ 6.71
Number of options, Outstanding at end of period	2,985,703	2,915,493	2,985,703	2,915,493
Weighted average exercise price, Outstanding at end of period	$ 5.41	$ 5.84	$ 5.41	$ 5.84
Number of options, Exercisable at end of period	2,228,902	2,090,378	2,228,902	2,090,378
Weighted average exercise price, Exercisable at end of period	$ 5.67	$ 5.59	$ 5.67	$ 5.59
Number of options, Non-vested at beginning of period	772,301	876,851	596,503	986,005
Weighted average exercise price, Non-vested at beginning of period	$ 4.67	$ 6.48	$ 5.53	$ 6.46
Number of options, Vested		(37,861)	(63,639)	(145,515)
Weighted average exercise price, Vested		$ 11.13	$ 6.75	$ 7.44
Number of options, Forfeited	(13,750)	(13,875)	(24,313)	(15,375)
Weighted average exercise price, Forfeited	$ 3.79	$ 5.9	$ 5.04	$ 6.73
Number of options, Non-vested at the end of period	758,551	825,115	758,551	825,115
Weighted average exercise price, Non-vested at the end of period	$ 4.68	$ 6.27	$ 4.68	$ 6.27

Share-Based Compensation (Det_3

Share-Based Compensation (Details) - Schedule of Exercise Prices and Remaining Contractual Life - Stock Options [Member]	6 Months Ended
	Jun. 30, 2024 USD ($) $ / shares shares
Schedule of Exercise Prices and Remaining Contractual Life [Line Items]
Number of options outstanding	2,985,703
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	2,228,902
Exercise Price One [Member]
Schedule of Exercise Prices and Remaining Contractual Life [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 2.69
Number of options outstanding	649,591
Remaining contractual Life (in years)	11 months 1 day
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	649,591
Exercise Price Two [Member]
Schedule of Exercise Prices and Remaining Contractual Life [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 3.21
Number of options outstanding	240,000
Remaining contractual Life (in years)	9 years 7 months 17 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable
Exercise Price Three [Member]
Schedule of Exercise Prices and Remaining Contractual Life [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 3.53
Number of options outstanding	53,192
Remaining contractual Life (in years)	9 years 4 months 6 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable
Exercise Price Four [Member]
Schedule of Exercise Prices and Remaining Contractual Life [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 3.66
Number of options outstanding	250,000
Remaining contractual Life (in years)	5 years 10 months 2 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	250,000
Exercise Price Five [Member]
Schedule of Exercise Prices and Remaining Contractual Life [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 4.68
Number of options outstanding	34,500
Remaining contractual Life (in years)	5 years 9 months
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	34,500
Exercise Price Six [Member]
Schedule of Exercise Prices and Remaining Contractual Life [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 5.34
Number of options outstanding	160,750
Remaining contractual Life (in years)	7 years 9 months
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	84,000
Exercise Price Seven [Member]
Schedule of Exercise Prices and Remaining Contractual Life [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 5.34
Number of options outstanding	442,410
Remaining contractual Life (in years)	8 years 4 months 20 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	178,176
Exercise Price Eight [Member]
Schedule of Exercise Prices and Remaining Contractual Life [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 5.96
Number of options outstanding	150,000
Remaining contractual Life (in years)	8 years 4 months 20 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	37,500
Exercise Price Nine [Member]
Schedule of Exercise Prices and Remaining Contractual Life [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 6.22
Number of options outstanding	552,883
Remaining contractual Life (in years)	2 years 8 months 1 day
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	552,883
Exercise Price Ten [Member]
Schedule of Exercise Prices and Remaining Contractual Life [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 8.19
Number of options outstanding	150,000
Remaining contractual Life (in years)	5 years 4 months 20 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	150,000
Exercise Price Eleven [Member]
Schedule of Exercise Prices and Remaining Contractual Life [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 9.02
Number of options outstanding	40,500
Remaining contractual Life (in years)	6 years 4 months 17 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	30,375
Exercise Price Twelve [Member]
Schedule of Exercise Prices and Remaining Contractual Life [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 10.12
Number of options outstanding	10,407
Remaining contractual Life (in years)	4 years 5 months 4 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	10,407
Exercise Price Thirteen [Member]
Schedule of Exercise Prices and Remaining Contractual Life [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 12.23
Number of options outstanding	250,000
Remaining contractual Life (in years)	6 years 10 months 28 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	250,000
Exercise Price Fourteen [Member]
Schedule of Exercise Prices and Remaining Contractual Life [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 21.4
Number of options outstanding	970
Remaining contractual Life (in years)	5 years 25 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	970
Exercise Price Fifteen [Member]
Schedule of Exercise Prices and Remaining Contractual Life [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 90.16
Number of options outstanding	500
Remaining contractual Life (in years)	5 months 1 day
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	500

Share-Based Compensation (Det_4

Share-Based Compensation (Details) - Schedule of Restricted Stock Units Granted Under the 2019 Plan - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Schedule of Restricted Stock Units Granted Under the 2019 Plan [Line Items]
Number of shares, Nonvested at beginning of period	571,460	114,329	621,135	157,560
Weighted average grant date fair value, Nonvested at beginning of period	$ 2.65	$ 9.97	$ 3.14	$ 10.02
Number of shares, Granted
Weighted average grant date fair value, Granted
Number of shares, Vested	(3,444)	(3,438)	(44,050)	(46,544)
Weighted average grant date fair value, Vested	$ 10.28	$ 10.28	$ 9.9	$ 10.15
Number of shares, Forfeited	(5,757)	(313)	(14,826)	(438)
Weighted average grant date fair value, Forfeited	$ 3.87	$ 14.67	$ 3.64	$ 14.67
Number of shares, Nonvested at end of period	562,259	110,578	562,259	110,578
Weighted average grant date fair value, Nonvested at end of period	$ 2.59	$ 9.95	$ 2.59	$ 9.95

Share-Based Compensation (Det_5

Share-Based Compensation (Details) - Schedule of Share-Based Compensation Expenses Related to Grants Under the 2019 Plan - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Schedule of Share-Based Compensation Expenses Related to Grants Under the 2019 Plan [Line Items]
Share-based compensation	$ 388	$ 511	$ 771	$ 1,144
Research & development [Member]
Schedule of Share-Based Compensation Expenses Related to Grants Under the 2019 Plan [Line Items]
Share-based compensation	145	122	269	318
General & administrative [Member]
Schedule of Share-Based Compensation Expenses Related to Grants Under the 2019 Plan [Line Items]
Share-based compensation	$ 243	$ 389	$ 502	$ 826

Fair Value Measurement (Details

Fair Value Measurement (Details) - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Cash and cash equivalents	$ 3,747	$ 813
Short term deposits	22,195	26,507
Restricted cash	306	413
Total financial assets	26,248	27,733
Level 1 [Member]
Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Cash and cash equivalents		813
Short term deposits		26,507
Restricted cash		413
Total financial assets		27,733
Level 2 [Member]
Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Cash and cash equivalents
Short term deposits
Restricted cash
Total financial assets
Level 3 [Member]
Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Cash and cash equivalents
Short term deposits
Restricted cash
Total financial assets

Events Subsequent to the Bala_2

Events Subsequent to the Balance Sheet Date (Details) - Subsequent Event [Member]	Jul. 31, 2024 shares
Pre-Funded Warrants [Member]
Events Subsequent to the Balance Sheet Date [Line Items]
Pre-funded warrants exercised	518,429
Common Stock [Member]
Events Subsequent to the Balance Sheet Date [Line Items]
Exercised ordinary shares	518,429